Atlas Trials

Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC

Clinical trial NCT07388875 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07388875
Sponsor
China Medical University, China
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Extensive-Stage Small Cell Lung Cancer
Start date
2026-02-24
Primary completion
2027-02-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.